Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104616 | 0.88 | — | — | |
| SCHEMBL104033 | 0.84 | MAPT (0.39) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL12496250 | 0.74 | PARP10 (0.44) | CA12CA9 | |
| Water SCHEMBL11215400 | 0.72 | MAPT (0.48) | MAPTKDM4ECA12CA1CA2 | |
| Water SCHEMBL28182961 | 0.72 | MAPT (0.48) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL18067051 | 0.72 | KDM4E (0.38) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL8556611 | 0.72 | MAPT (0.58) | MAPTCA9LMNA | |
| SCHEMBL3813285 | 0.72 | MEN1 (0.34) | MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL104221 | 0.71 | — | — | |
| SCHEMBL3884745 | 0.71 | PNMT (0.41) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 962 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | claimed |
| WO-2023150526-A1 | COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | claimed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-15 | — | — | US | claimed |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | claimed |
| US-9855267-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-01-02 | — | — | US | claimed |
| EP-0702680-A1 | 2-OXO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-03-27 | — | — | EP | claimed |
| EP-0704067-A4 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES INC (US) | 1996-02-02 | — | — | EP | claimed |
| EP-0216483-B2 | Thermal transfer printing | ZENECA LTD (GB) | 1995-11-02 | — | — | EP | claimed |
| US-5458815-A | Photochromic naphthopyran compounds | TRANSITIONS OPTICAL, INC. (US) | 1995-10-17 | — | — | US | claimed |
| WO-1995000866-A1 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1995-01-05 | — | — | WO | claimed |
| WO-1994029297-A1 | 2-OXO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-12-22 | — | — | WO | claimed |
| EP-0216483-B1 | THERMAL TRANSFER PRINTING | ZENECA LIMITED (GB) | 1990-04-11 | — | — | EP | claimed |
| EP-0216483-A1 | Thermal transfer printing | ZENECA LIMITED (GB) | 1987-04-01 | — | — | EP | claimed |
| US-4132436-A | Recording material | FUJI PHOTO FILM CO., LTD. (JP) | 1979-01-02 | — | — | US | claimed |
| US-4119777-A | BY OXIDATION OF A THIOAMIDE DERIVATIVE | FUJI PHOTO FILM CO., LTD. (JP) | 1978-10-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | MTHFD1, MTHFD2, DPYD | MAPT 1714/4885KDM4E 3062/4885CA12 4338/4885 |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | MAPT 845/4885KDM4E 384/4885CA12 3539/4885 |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | WAPL, WHR1, G3BP1 | MAPT 3975/4885KDM4E 1647/4885CA12 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.